BANGKOK, THAILAND, July 12 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT)
and the Abbott Laboratories Fund today announced that program results and key
learnings from the company's Global Care Initiatives would be highlighted in
more than 30 presentations at the XV International AIDS Conference taking
place this week in Bangkok. Abbott Laboratories is investing $100 million
over five years in the fight against HIV/AIDS through four programs that
address areas of critical need in developing countries: services to care for
orphans and vulnerable children with Step Forward; the improvement of health
care infrastructure with Tanzania Care; access to testing and treatment
through Abbott Access to HIV Care; and the prevention of mother-to-child
transmission (PMTCT) of HIV with the Determine HIV(R) Testing Donation
"Through effective partnerships among government, nongovernmental
organizations (NGOs) and industry, replicable models can be created that
deliver results in fighting HIV/AIDS," said Reeta Roy, divisional vice
president, Global Citizenship and Policy, Abbott Laboratories. "With the
recent increase in international funding for HIV/AIDS initiatives in
developing countries, there is a great need to identify programs that have
shown demonstrable results. We look forward to sharing the results and key
learnings from our programs with the global HIV community."
Program results to be discussed at the conference include:
-- Reducing pediatric AIDS mortality by more than two-thirds (15 percent
to 3 percent) in Constanta, Romania, through the care provided by a
comprehensive pediatric HIV clinic funded by the Step Forward program.
This successful model is being replicated in other countries through
the work of the Baylor International Pediatric AIDS Initiative.
-- Serving more than 140,000 orphans and vulnerable children through the
Step Forward program in 2003; program results included creating lasting
change in reducing stigma and providing support for children and
families affected by HIV in India by working through existing community
organizations, such as economic development groups.
-- Modernizing Muhimbili National Hospital in Dar es Salaam, the capital
of Tanzania, including the development of modern hospital systems and
construction of a new outpatient department to strengthen its role as
Tanzania's principal referral, teaching and research facility.
-- Extending the capacity for voluntary counseling and testing (VCT) in 16
regional Tanzanian hospitals, reaching deep into both rural and urban
-- Donating more than 1 million Determine HIV tests to PMTCT programs in
developing countries. Abbott recently extended its PMTCT donations to
include testing of spouses and children of pregnant women who are found
to be HIV positive through the program.
-- Providing 6.7 million Determine HIV tests, at no profit, for HIV
programs conducting VCT in 2003, nearly a three-fold increase since
"Working together with Abbott's Step Forward program, we've been able to
make a significant difference in the lives of hundreds of children in Romania
through the creation of a state-of-the-art pediatric HIV/AIDS treatment
center," said Mark Kline, M.D., director of Baylor's International Pediatric
AIDS Initiative. "With Abbott's continued support, we're building on our
successful Romanian model by establishing a coordinated network of pediatric
HIV/AIDS centers in other countries, including Botswana, Mexico and Uganda,
that will enhance the care of children with HIV/AIDS around the world."
About Abbott's Global Care Initiatives
Abbott's Global Care Initiatives respond to the HIV/AIDS crisis through
four targeted programs in developing countries around the world:
* Step Forward was created by Abbott and the Abbott Laboratories Fund to
improve the lives of orphans and vulnerable children impacted by
HIV/AIDS. Step Forward works with international and local partners
(Axios, Baylor College of Medicine, International HIV/AIDS Alliance,
local governments and in-country NGOs) to address specific community
needs through four critical activities: education, health services and
infrastructure, voluntary counseling and testing, and provision of basic
* Tanzania Care is a partnership among Abbott, the Abbott Laboratories
Fund and the Government of Tanzania to modernize the country's public
health care facilities and systems, and to improve services and access
to care for people living with HIV/AIDS and other serious illnesses.
The overarching goal of Tanzania Care is to create a public/private
model that can be adapted by other companies and organizations working
to fight AIDS in the developing world.
In collaboration with Axios, its implementing partner, Tanzania Care
focuses largely on renovating and modernizing Muhimbili National
Hospital, the country's largest public health facility, and enhancing
its position as Tanzania's primary research, referral and teaching
facility and as a "center of excellence" for the entire region. The
program also covers regional hospitals and laboratories, modernizing
systems, increasing training of medical workers and laboratory
personnel, and expanding access to VCT for HIV.
* Abbott Access to HIV Care is the company's direct contribution to the
fight against AIDS through broadened access to Abbott's HIV diagnostic
tests and therapies in 69 countries, including all of Africa. The
company provides two antiretroviral drugs, Kaletra(R)
(lopinavir/ritonavir) and Norvir(R) (ritonavir) at a loss to Abbott. In
addition, Abbott is the only pharmaceutical company to provide a rapid
HIV diagnostic test, Determine HIV, at no profit for VCT programs in
developing countries. Abbott Access to HIV Care is available to any
organization or institution that provides products to patients as part
of a sound and sustainable program of care.
* Determine HIV Testing Donation Program provides Determine HIV rapid
tests free of charge to programs for the prevention of mother-to-child
transmission (PMTCT) of HIV/AIDS in 69 countries, including all of
Africa. Abbott partners with leading organizations working in PMTCT and
cooperates with Boehringer Ingelheim, which provides free HIV treatment
to prevent transmission of HIV from mother to child.
Additional information about Abbott Laboratories Global Care Initiatives,
including information on presentations and activities at the XV International
AIDS Conference, is available at http://www.abbottglobalcare.org .
Abbott Laboratories has been a leader in HIV/AIDS research since the early
years of the epidemic. In 1985, the company developed the first licensed test
to detect HIV antibodies in the blood, and remains a leader in HIV
diagnostics. Abbott retroviral and hepatitis tests are used to screen more
than half of the world's donated blood supply. Abbott also has developed two
protease inhibitors for the treatment of HIV/AIDS.
Abbott Laboratories is a global, broad-based health care company devoted
to the discovery, development, manufacture and marketing of pharmaceuticals
and medical products, including nutritionals, devices and diagnostics. The
company employs more than 55,000 people and markets its products in more than
Abbott's news releases and other information are available on the
company's Web site at http://www.abbott.com .
SOURCE Abbott Laboratories
Web Site: http://www.abbottglobalcare.org